Factor VIII Procoagulant Protein Interacts with Phospholipid Vesicles Via its 80 kDa Light Chain

Summary

In a previous report, we detailed the fractionation of polyclonal human anti-Factor VIII :C into a component directed exclusively against the phospholipid-binding site on Factor VIII (PL-site antibody) and another directed at other sites (non-PL-site antibody). The location on the F.VIII molecule of its PL-binding site has now been studied by two different methods using this fractionated ¹²⁵I-labelled anti-F.VIII: C Fab’.

The first method was modified from that of Weinstein et al. (Proc Natl Acad Sci USA 1981; 78: 5137-41), involving electrophoresis of F.VIII peptide-¹²⁵I-Fab‘ A/F.VIII immunocomplexes in SDS-polyacrylamide gels. PL-site antibody reacted with F.VIII peptides of apparent M_r approximately 80 kDa and sometimes 160 kDa in plasma and concentrate, but not with larger peptides. Non-PL-site antibody, however, reacted with a range of peptides of apparent M_r 90 kDa to 280 kDa. In addition, when purified F.VIII containing heavy and light chains (HC + LC), and isolated LC peptides were analysed, PL-site antibody bound to LC peptides whereas non-PL-site antibody did not.

The second method used the antibody pools in immunoradiometric assays (IRMA’s) of purified F.VIII peptides. Both labels measured similar amounts of F.VIII: Ag in a sample of purified F.VIII containing both HC and LC; on assaying an HC preparation, however, PL-site label measured only 2% of F.VIII: Ag found by non-PL-site label, indicating that PL-binding sites are absent in HC preparations.

These results indicate that F.VIII binds to PL via its 80 kDa light chain.

Key words

Factor VIII - Phospholipid - Antibodies - Immunocomplexes

• References

• 1 van Dieijen G, van Rijn JL M L, Govers-Riemslag JW P, Hemker HC, Rosing J. Assembly of the intrinsic factor X activating complex: interactions between factor IXa, factor VIIIa and phospholipid. Thromb Haemostas 1985; 53: 396-400
• 2 Mertens K, van Wijngaarden A, Bertina RM. The role of factor VIII in the activation of human blood coagulation factor X by activated factor IX. Thromb Haemostas 1985; 54: 654-660
• 3 Vehar GA, Keyt B, Eaton D, Rodriguez H, O’Brien DR, Rotblat E, Oppermann H, Keck R, Wood WI, Harkins RN, TUddenham EG D, Lawn RM, Capon DJ. Structure of human factor VIII. Nature 1984 312: 337-342
• 4 Toole JJ, Knopf JL, Wozney JM, Sultzman LA, Buecker JL, Pittman DD, Kaufman RJ, Brown E, Shoemaker C, Orr EC, Amphlett GW, Foster BW, Coe ML, Knutson GJ, Fass DN, Hewick RM. Molecular cloning of a cDNA encoding human antihaemophilic factor. Nature 1984; 312: 342-347
• 5 O’Brien DP. Puritication and Characterisation of Human Factor VIII. PhD Thesis, University of London, London 1985
• 6 Fulcher CA, Roberts JR, Holland LZ, Zimmerman TS. Human factor VIII procoagulant protein: monoclonal antibodies define precursor-product relationships and functional epitopes. J Clin Invest 1985; 76: 117-124
• 7 Andersson L-O, Forsmatr N, Huang K, Larsen K, Lundin A, Pavlu B, Sandberg H, Sewerin K, Smart J. Isolation and characterisation of human factor VIII: molecular forms in commercial factor VIII concentrate, cryoprecipitate and plasma. Proc Natl Acad Sci USA 1986; 83: 2979-2983
• 8 Eaton D, Rodriguez H, Vehar GA. Proteolytic processing of human factor VIII. Correlation of specific cleavages by thrombin, factor Xa and activated protein C with activation and inactivation of factor VIII coagulant activity. Biochemistry 1986 25. 505-512
• 9 Kemball-Cook G, Barrowcliffe TW. Fractionation of human antibody to Factor VIII: C: an IRMA for phospholipid binding sites on Factor VIII C:Ag. Br J Haematol 1984; 57: 633-636
• 10 Weinstein M, Chute L, Deykin D. Analysis of factor VIII coagulant antigen in normal, thrombin-treated and haemophilic plasma. Proc Natl Acad Sci USA 1981; 78: 5137-5141
• 11 Barrowcliffe TW, Edwards SJ, Kemball-Cook G, Thomas DP. Factor VIII degradation products in heated concentrates. Lancet 1986; 2: 1448-1449
• 12 Kemball-Cook G, Barrowcliffe TW. Factor VIII concentrates contain Factor VIII procoagulant antigen bound to phospholipid. Br J Haematol 1986; 63: 425-434
• 13 Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970; 227: 680-685
• 14 Barrowcliffe TW, Kemball-Cook G, Gray E. Binding to phospholipid protects Factor VIII from inactivation by human antibodies. J Lab Clin Med 1983; 101: 34-43
• 15 van Rijn JL M L, Zwaal RF A, Hemker HC, Rosing J. Role of accessory components in the activation of vitamin K-dependent factors. Haemostasis 1986; 16: 216-226
• 16 Jenny RJ, Pittmann DD, Toole JJ, Kriz RW, Aldape RA, Hewick RM, Kaufman RJ, Mann KG. Complete cDNA and derived amino acid sequence of human factor V. Proc Natl Acad Sci USA 1987; 84: 4846-4850
• 17 Kane WH, Davie EW. Blood coagulation factors V and VIII: structural and functional similarities and their relationship to hemorrhagic and thrombotic disorders. Blood 1988; 7l: 539-555
• 18 Suzuki K, Dahlbnck B, Stenflo J. Thrombin-catalysed activation of human coagulation factor V. J Biol Chem 1982; 257: 6556-6564
• 19 van de Waart P, Bruls H, Hemker HC. Lindhout T Interaction of bovine blood clotting factor Va and its subunits with phospholipid vesicles. Biochemistry 1983; 22: 2427-2432
• 20 Mayer LD, Pusey ML, Griep MA, Nelsestuen GL. Association of blood coagulation factors V and X with phospholipid monolayers. Biochemistry 1983; 22: 6226-6232
• 21 Pusey ML, Nelsestuen GL. Membrane-binding properties of blood coagulation factor V and derived peptides. Biochemistry 1984; 23: 6202-6210
• 22 Toqle JJ, Pittman D, Murtha P, Wasley LC, Wang J, Amphlett G, Hewick R, Foster WB, Kametr R, Kaufman RJ. Exploration of structure-function relationships in human factor VIII by site-directed mutagenesis. Cold Spring Harbour Symp Quant Biol 1986; 51: 548-549
• 23 Miletich JR, Jackson CM, Majerus PW. Properties of the factor Xa binding site on human platelets. J Biol Chem 1978; 253: 6908-6916
• 24 Tracy PB, Peterson JM, Nesheim ME, McDuffie FC, Mann KG. Interaction of coagulation factor V and Va with platelets. J Biol Chem 1979; 254: 10354-10361
• 25 Elödi S, Váradi K. Optimisation of conditions for the catalytic effect of the factor IXa-factor VIII complex. Probable role of the complex in the amplification of blood coagulation. Thromb Res 1979 15. 617-629
• 26 Elödi S, Váradi K, Vörös E. Kinetics of formation of factor IXa-factor VIII complex on the surface of platelets. Thromb Res 1981; 21: 695-700
• 27 Muntean W, Leschnik B, Haas J. Factor VIII coagulant moiety binds to platelets by binding to phospholipids of the platelet membrane. Thromb Res 1987; 45: 345-354
• 28 Kemball-Cook G. Interaction of Factor VIII Clotting Protein with Phospholipids. PhD Thesis, CNAA 1987; Chapter 7
• 29 Bloom JW. The interaction of rDNA factor VIII, factor VIII_{des,-797-1562}and factor VIII_des-7e7-1567derived peptides with phospholipid. Thromb Res 1987; 48: 439-448